Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

3.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 560
Open 3.900
Bid (Size) 3.960 (1)
Ask (Size) 4.000 (4)
Prev. Close 3.900
Today's Range 3.900 - 3.900
52wk Range 1.150 - 6.230
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue. 
Via InvestorPlace
Exposures Product Safety

Performance

YTD
+94.03%
+94.03%
1 Month
-6.70%
-6.70%
3 Month
+63.18%
+63.18%
6 Month
+178.57%
+178.57%
1 Year
+204.69%
+204.69%

More News

Read More
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Dow Surges 350 Points; Fed Holds Rates Steady
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Crude Oil Surges 2%; Signet Jewelers Shares Spike Higher
Via Benzinga
Topics Economy Stocks
Exposures Fossil Fuels Interest Rates US Equities
A Stock Split Catalyst Looms for Chipotle (CMG) Stock on June 6
Via InvestorPlace
INTC Stock Alert: Intel Just Got a Major $8.5 Billion Boost
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today?
Via InvestorPlace
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.